Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma Interventions:   Drug: Lenvatinib;   Drug: Placebo;   Drug: Immunosuppressive regimen Sponsor:   RenJi Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials